Article Sidebar
Views pdf: 236
TREATMENT OUTCOMES OF HELICOBACTER PYLORI ERADICATION USING BISMUTH QUADRUPLE THERAPY AT 103 CAM KHI CLINIC
Main Article Content
Abstract
Objectives: To evaluate treatment outcomes of helicobacter pylori eradication using bismuth quadruple therapy. Subjects and methods: We conducted an interventional study on 51 patients with indication of Helicobacter pylori eradication at 103 Cam Khe Clinic from January 2019 to December 2021. Results: Female accounted for 78.6%, male accounted for 21.6%. The age group 35-49 accounted for 60.8%. Ulcer in antrum accounts for 39.2%, ulcer size less than 1 cm accounts for 60.8%, only 1 ulcer accounts for 94.1%. Side effects appeared as: fatigue accounted for 25.5%, anorexia accounted for 23.5%... The H.p eradication rate in patients with Bismuth was 92.2%.
Article Details
Keywords
Helicobacter pylori, bismuth, peptic ulcer
References
2. Đặng Ngọc Quý Huệ, Trần Văn Huy, Nguyễn Thanh Hải (2016). Viêm dạ dày mạn do Helicobacter pylori: Hiệu quả tiệt trừ của phác đồ bốn thuốc có bismuth (EBMT). Tạp chí y dược học;32:149 - 158.
3. Trần Đình Cường, Trần Văn Huy (2017). Đánh giá hiệu quả của phác đồ RBMT ở bệnh nhân viêm dạ dày mạn nhiễm Helicobacter pylori đã thất bại với phác đồ 3 thuốc. Tạp chí Nội khoa Việt Nam: 206 - 214.
4. Trần Thị Khánh Tường (2017). Hiệu quả điều trị của phác đồ 4 thuốc có bismuth trong điều trị nhiễm Helicobacter pylori. Tạp chí Y Dược học; 7: 29 - 34.
5. Malfertheiner P, Megraud F, O'Morain CA, et al (2016). Management of Helicobacter pylori infection - - the Maastricht V/ Florence Consensus Report. Gut.;61(5):646 - 664.
6. Xie, Y.; Zhu, et al (2018). Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: A Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China. Antimicrob. Agents Chemother. 62, e00432-18.
7. Wu, M.C.; Wang, Y.K (2017). Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori. Gastroenterol. Res. Pract. , 5320180.
8. Bang, C.S.; Lim, H.; Jeong, H.M (2020). Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection. Gut Microbes, 11, 1314–1323.